AS
Altshuler Shaham Portfolio holdings
AUM
$3.14B
1-Year Return
24.55%
This Quarter Return
+8.69%
1 Year Return
+24.55%
3 Year Return
+51.84%
5 Year Return
+71.45%
10 Year Return
–
AUM
$13.4B
AUM Growth
+$3.68B
(+38%)
Cap. Flow
+$2.83B
Cap. Flow
% of AUM
21.1%
Top 10 Holdings %
Top 10 Hldgs %
62.09%
Holding
768
New
329
Increased
131
Reduced
103
Closed
165
Top Buys
| 1 |
TSMC
TSM
|
$338M |
| 2 |
Microsoft
MSFT
|
$303M |
| 3 |
Alibaba
BABA
|
$301M |
| 4 |
Apple
AAPL
|
$214M |
| 5 |
Amazon
AMZN
|
$151M |
Top Sells
| 1 |
Global X Cybersecurity ETF
BUG
|
$581M |
| 2 |
Open Text
OTEX
|
$60.3M |
| 3 |
iShares MSCI ACWI ETF
ACWI
|
$5.94M |
| 4 |
Nova
NVMI
|
$5.57M |
| 5 |
Synchrony
SYF
|
$3.9M |
Sector Composition
| 1 | Technology | 43.36% |
| 2 | Consumer Discretionary | 13.36% |
| 3 | Communication Services | 11.23% |
| 4 | Financials | 9.42% |
| 5 | Consumer Staples | 6.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
301
Surmodics
SRDX
$463M
| $115K | ﹤0.01% |
+2,112
| New | +$115K |
|
302
CONMED
CNMD
$1.7B
| $114K | ﹤0.01% |
+826
| New | +$114K |
|
303
Inogen
INGN
$219M
| $114K | ﹤0.01% |
1,746
+923
| +112% | +$60.3K |
|
304
Organogenesis Holdings
ORGO
$634M
| $114K | ﹤0.01% |
6,858
+4,245
| +162% | +$70.6K |
|
305
CRISPR Therapeutics
CRSP
$4.99B
| $113K | ﹤0.01% |
700
-300
| -30% | -$48.4K |
|
306
Donnelley Financial Solutions
DFIN
$1.55B
| $113K | ﹤0.01% |
3,420
+347
| +11% | +$11.5K |
|
307
Eli Lilly
LLY
$652B
| $113K | ﹤0.01% |
31,767
+269
| +0.9% | +$957 |
|
308
Labcorp
LH
$23.2B
| $112K | ﹤0.01% |
+474
| New | +$112K |
|
309
Envista
NVST
$3.54B
| $112K | ﹤0.01% |
2,602
+1,595
| +158% | +$68.7K |
|
310
United Therapeutics
UTHR
$18.1B
| $112K | ﹤0.01% |
623
+5
| +0.8% | +$899 |
|
311
Catalyst Pharmaceutical
CPRX
$2.48B
| $110K | ﹤0.01% |
+19,060
| New | +$110K |
|
312
AbbVie
ABBV
$375B
| $109K | ﹤0.01% |
969
-47
| -5% | -$5.29K |
|
313
Nice
NICE
$8.67B
| $108K | ﹤0.01% |
+435
| New | +$108K |
|
314
Phibro Animal Health
PAHC
$1.6B
| $108K | ﹤0.01% |
+3,746
| New | +$108K |
|
315
Teladoc Health
TDOC
$1.38B
| $108K | ﹤0.01% |
650
| – | – |
|
316
Lockheed Martin
LMT
$108B
| $107K | ﹤0.01% |
286
-769
| -73% | -$288K |
|
|
RDS.A
317
DELISTED
Royal Dutch Shell PLC ADS Class A
RDS.A
| $107K | ﹤0.01% |
2,650
| – | – |
|
318
CVS Health
CVS
$93.6B
| $104K | ﹤0.01% |
+1,245
| New | +$104K |
|
319
Quest Diagnostics
DGX
$20.5B
| $103K | ﹤0.01% |
+778
| New | +$103K |
|
|
320
Synchrony
SYF
$28.1B
| $102K | ﹤0.01% |
2,105
-80,416
| -97% | -$3.9M |
|
321
Karyopharm Therapeutics
KPTI
$57.2M
| $101K | ﹤0.01% |
+649
| New | +$101K |
|
322
iShares MSCI All Country Asia ex Japan ETF
AAXJ
$2.89B
| $99K | ﹤0.01% |
+1,335
| New | +$99K |
|
323
Vericel Corp
VCEL
$1.72B
| $99K | ﹤0.01% |
1,879
-573
| -23% | -$30.2K |
|
324
Bread Financial
BFH
$3.09B
| $88K | ﹤0.01% |
1,056
+768
| +267% | +$64K |
|
325
Recon Technology
RCON
$60.6M
| $87K | ﹤0.01% |
+1,113
| New | +$87K |
|